

**Current Pharmaceutical Biotechnology Special Issue Call
for Papers:**

**ADVANCE IN BIOLOGICAL TARGETS
FOR INFLAMMATION, IMMUNITY AND
CANCER-RELATED DISEASES**

Section Editor: Professor Donghua Xu

Affiliation: Affiliated Hospital of Weifang Medical University

Email Address: flower322@163.com & xudh@wfmc.edu.cn

Submission start: November 2020

Submission deadline: April 2021

Scope and Perspective

This special issue in *Current Pharmaceutical Biotechnology (CPB)* aims at publishing high-quality original research as well as reviews on advance in biological targets for inflammation, immunity and cancer-related diseases, particularly regarding the latest and outstanding developments in Pharmaceutical Biotechnology.

Potential topics of interest include but are not limited to:

1. Biological targets research for inflammation and autoimmune disease (Basic, clinical or pre-clinical)
2. Biological targets research for cancer (Basic, clinical or pre-clinical)
3. Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
4. Functional genomics in inflammation, immunity and cancer.
5. Regenerative medicine (stem cells, tissue engineering and biomaterials)
6. Molecular pharmaceuticals and molecular pharmacology

Article types:

- **Original research:** 5-7 full length articles.
- **Review:** 1-2 review articles.

Invited review:

Author Name: Professor Donghua Xu

Institutional Affiliation: Affiliated Hospital of Weifang Medical University

E-mail: flower322@163.com & xudh@wfmw.edu.cn

Title: Mesenchymal Stem Cell-derived Extracellular Vesicles: Effects on Placentation and Pregnancy Disorders.

Article type: review.

Deadline for submission: March 2020.

Original research contribution:

Author Name: Professor Caihong Liang

Institutional Affiliation: Affiliated Jiangning Hospital with Nanjing Medical University

E-mail: lch@njmu.edu.cn

Title: PTPRO is a diagnostic marker for coronary heart disease

Article type: original research.

Deadline for submission: Dec. 31, 2019.

Other possible contributions:

1. **Author Name:** Michael Karin

Institutional Affiliation: Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California San Diego

E-mail: karinoffice@ucsd.edu

Deadline for submission: April 2020

2. **Author Name:** Alan Prem Kumar

Institutional Affiliation: Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore

E-mail: csiapk@nus.edu.sg

Deadline for submission: April 2020

3. **Author Name:** Amirhossein Sahebkar

Institutional Affiliation: Halal Research Center of IRI, FDA, Tehran, Iran;
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad
University of Medical Sciences, Mashhad, Iran

E-mail: sahebkar@mums.ac.ir

Deadline for submission: April 2020

4. **Author Name:** Kavita M Dhodapkar

Institutional Affiliation: Emory University and Children's Healthcare of Atlanta,
Atlanta, GA, United States.

E-mail: kavita.dhodapkar@emory.edu

Deadline for submission: April 2020